药易购(300937) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥1,007,512,528.99, representing an increase of 8.99% compared to the same period last year[5] - Net profit attributable to shareholders decreased by 63.74% to ¥3,439,600.69, while the net profit after deducting non-recurring gains and losses fell by 59.42% to ¥2,874,958.49[5] - Total operating revenue for Q3 2023 reached CNY 3,212,357,594.74, an increase of 19.7% compared to CNY 2,682,648,601.59 in the same period last year[22] - Net profit for Q3 2023 was CNY 49,645,720.30, significantly higher than CNY 9,424,419.53 in Q3 2022, marking a year-over-year increase of 426.5%[23] - The total comprehensive income for the third quarter was CNY 51,142,720.30, compared to CNY 9,424,419.53 in the previous year[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,625,286,638.97, reflecting a 2.12% increase from the end of the previous year[5] - The company's total assets as of Q3 2023 amounted to CNY 1,625,286,638.97, compared to CNY 1,591,618,007.45 at the end of the previous year[20] - The total liabilities for Q3 2023 were CNY 775,892,192.31, slightly up from CNY 771,641,954.49 in the previous period[20] - The company's total equity attributable to shareholders increased by 3.80% to ¥844,880,451.30 compared to the end of the previous year[5] - The total equity attributable to shareholders of the parent company rose to CNY 844,880,451.30, up from CNY 813,943,586.42 in the previous year[20] Cash Flow - The company reported a significant cash flow deficit from operating activities, with a net cash outflow of ¥-128,853,482.60, a decrease of 544.65% compared to the same period last year[11] - The net cash flow from operating activities was negative at CNY -128,853,482.60, compared to a positive CNY 28,978,498.23 in the previous year[27] - Cash outflow from operating activities totaled CNY 3,391,258,205.22, up from CNY 2,161,982,560.14 in the previous year[27] - The net cash flow from investing activities was CNY -12,483,357.71, an improvement from CNY -18,791,341.52 in the previous year[27] - The net cash flow from financing activities was CNY -71,586,045.20, compared to a positive CNY 33,052,442.00 in the previous year[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,425[13] - The largest shareholder, Li Yanfei, holds 36.97% of the shares, totaling 35,370,000 shares[13] - The top ten shareholders include Chengdu Boyuan New航创业投资基金 with 2,148,200 shares, accounting for 2.25%[14] - The total number of shares held by the top ten shareholders represents a significant concentration of ownership, with the top three holding over 49%[13] - The company has a total of 54,555,100 restricted shares, with 91,650 shares released during the period[17] Expenses - Sales expenses rose by 33.05% to ¥143,155,370.65, driven by increased staffing and e-commerce operational costs[11] - The company’s management expenses increased by 38.72% to ¥42,071,281.81, due to the expansion of subsidiaries and increased personnel costs[11] - Research and development expenses for Q3 2023 were CNY 14,122,063.35, compared to CNY 13,096,920.83 in Q3 2022, indicating a year-over-year increase of 7.8%[23] Accounts Receivable and Inventory - The company's accounts receivable increased by 516.81% to ¥427,627,644.01, attributed to a credit sales policy implemented for major clients[9] - Accounts receivable increased to ¥427,627,644.01 from ¥69,328,543.14 at the beginning of the year[18] - The company’s inventory as of Q3 2023 was CNY 452,606,615.63, a slight increase from CNY 446,784,471.05 in the previous quarter[19] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[17] - The company has not indicated any plans for mergers or acquisitions in the near future[17] - The company has not undergone an audit for the third quarter report[28] - Basic and diluted earnings per share for the quarter were CNY 0.52, up from CNY 0.18 in the same period last year[24] - The company reported cash and cash equivalents of ¥251,736,712.23 as of September 30, 2023, down from ¥457,824,436.55 at the beginning of the year[18]